Botulinum toxin type a versus topical 20% aluminum chloride for the treatment of moderate to severe primary focal axillary hyperhidrosis

Journal of Drugs in Dermatology

Volumn 7, Issue 3, 2008, Pages 221-227

  Flanagan, Katherine H ^a   King, Rosemary ^a   Glaser, Dee Anna ^a  

^a SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALUMINUM CHLORIDE; ALUMINUM DERIVATIVE; ASTRINGENT AGENT; BOTULINUM TOXIN A; CHLORIDE; NEUROTOXIN;

ADULT; ARTICLE; AXILLA; CLINICAL TRIAL; COMPARATIVE STUDY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEMALE; HOSPITALIZATION; HUMAN; HYPERHIDROSIS; INJECTION; MALE; NONPARAMETRIC TEST; PATHOLOGY; PATIENT SATISFACTION; RANDOMIZED CONTROLLED TRIAL; SICKNESS IMPACT PROFILE; TOPICAL DRUG ADMINISTRATION; TREATMENT OUTCOME;

ADMINISTRATION, TOPICAL; ADULT; ALUMINUM COMPOUNDS; ASTRINGENTS; AXILLA; BOTULINUM TOXIN TYPE A; CHLORIDES; FEMALE; HUMANS; HYPERHIDROSIS; INJECTIONS; MALE; NEUROTOXINS; PATIENT SATISFACTION; SEVERITY OF ILLNESS INDEX; SICKNESS IMPACT PROFILE; STATISTICS, NONPARAMETRIC; TREATMENT OUTCOME;

EID: 47249123742     PISSN: 15459616     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (4)

1. Strutton DR, Kowalski JW, Glaser DA, Stang PE. US prevalence of hyperhidrosis and impact on individuals with axillary hyperhidrosis: results from a national survey. J Am Acad Dermatol. 2004; 51:241-248.
2. BOTOX® (botulinum toxin type A) [package insert]. Irvine, CA: Allergan, Inc.; October 2004.
3. Naumann M, Lowe NJ. Botulinum toxin type A in treatment of bilateral primary axillary hyperhidrosis: randomised, parallel group, double blind, placebo controlled trial. BMJ. 2001;323:596-599. (Pubitemid 32846124)
4. Lowe NJ, Glaser DA, Eadie N, et al. Botulinum toxin type A in the treatment of primary axillary hyperhidrosis: a 52-week multicenter double-blind, randomized, placebo-controlled study of efficacy and safety. J Am Acad Dermatol. 2007;56:604-611. (Pubitemid 46400197)